Olverembatinib: all 27 studies that test it
Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Phase 2
- Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentRecruitingNCT07282093Phase 1
- Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)Not yet recruitingNCT07178912Phase 2
- Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Phase 3
- Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.RecruitingNCT07074496Early Phase 1
- Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibRecruitingNCT06817720Phase 2
- Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLRecruitingNCT06757855Phase 1/2
- Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingNCT06754267Phase 2
- A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Phase 3
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Not applicable
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingNCT06401603Phase 1
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
- Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaRecruitingNCT06082934Phase 1/2
- A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)RecruitingNCT06051409Phase 3
- A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALLNot yet recruitingNCT05931757Phase 2
- Olverembatinib for FGFR1-rearranged NeoplasmsRecruitingNCT05521204Phase 2
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
- A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Phase 1
- Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCTWithdrawnNCT05604755Phase 2
- Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
- A Study of Olverembatinib in the Treatment of Ph+ ALLStatus unknownNCT05466175Phase 2
- Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.Status unknownNCT05311943Phase 3
- The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansCompletedNCT04126707Phase 1
- A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2
- A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2
- A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationStatus unknownNCT03883087Phase 2
- Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Phase 1